This week, the NHS approved two cannabis-derived medicines for the first time. It is a positive step for the future of legal cannabis in England.
UK Medicines and Healthcare Products Regulatory Agency Approves CBD The British government on Tuesday announced it is backing products containing a specific cannabinoid (a component of marijuana). Government health authorities have given private companies 28 days to get licenses to sell their products. The UK Medicines and Healthcare Products Regulatory Agency will approve products with the
By Alex Newman | Published in The New American On the 50th anniversary of the United Nations treaty that led to the global “War on Drugs,” a group of prominent officials and legislators from the United Kingdom declared the battle a failure and formed a commission calling for new policies to deal with problems associated with drugs.
Sativex®, available as a prescription only medicine, was developed by GW in specific response to calls from people with MS for a prescription cannabis-based medicine. Today’s launch means that MS patients suffering the spasms and cramping associated with spasticity have access to a new treatment option which has been shown to improve their symptoms where current treatments have failed.
Sativex® is manufactured by GW under Home Office licence at an undisclosed location in the UK. The medicine is being marketed in the UK by GW’s UK licensee, Bayer Schering Pharma.